Literature DB >> 24798303

Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome.

Sonya Parpart1, Stephanie Roessler, Fei Dong, Vinay Rao, Atsushi Takai, Junfang Ji, Lun-Xiu Qin, Qing-Hai Ye, Hu-Liang Jia, Zhao-You Tang, Xin Wei Wang.   

Abstract

UNLABELLED: Globally, hepatocellular carcinoma (HCC) accounts for 70%-85% of primary liver cancers and ranks as the second leading cause of male cancer death. Serum alpha-fetoprotein (AFP), normally highly expressed in the liver only during fetal development, is reactivated in 60% of HCC tumors and associated with poor patient outcome. We hypothesize that AFP+ and AFP- tumors differ biologically. Multivariable analysis in 237 HCC cases demonstrates that AFP level predicts poor survival independent of tumor stage (P<0.043). Using microarray-based global microRNA (miRNA) profiling, we found that miRNA-29 (miR-29) family members were the most significantly (P<0.001) down-regulated miRNAs in AFP+ tumors. Consistent with miR-29's role in targeting DNA methyltransferase 3A (DNMT3A), a key enzyme regulating DNA methylation, we found a significant inverse correlation (P<0.001) between miR-29 and DNMT3A gene expression, suggesting that they might be functionally antagonistic. Moreover, global DNA methylation profiling reveals that AFP+ and AFP- HCC tumors have distinct global DNA methylation patterns and that increased DNA methylation is associated with AFP+ HCC. Experimentally, we found that AFP expression in AFP- HCC cells induces cell proliferation, migration, and invasion. Overexpression of AFP, or conditioned media from AFP+ cells, inhibits miR-29a expression and induces DNMT3A expression in AFP- HCC cells. AFP also inhibited transcription of the miR-29a/b-1 locus, and this effect is mediated through c-MYC binding to the transcript of miR-29a/b-1. Furthermore, AFP expression promotes tumor growth of AFP- HCC cells in nude mice.
CONCLUSION: Tumor biology differs considerably between AFP+ HCC and AFP- HCC; AFP is a functional antagonist of miR-29, which may contribute to global epigenetic alterations and poor prognosis in HCC.
© 2014 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798303      PMCID: PMC4146718          DOI: 10.1002/hep.27200

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Paper electrophoretic study of human fetal serum proteins with demonstration of a new protein fraction.

Authors:  C G BERGSTRAND; B CZAR
Journal:  Scand J Clin Lab Invest       Date:  1957       Impact factor: 1.713

2.  Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level.

Authors:  C Balsano; M L Avantaggiati; G Natoli; E De Marzio; H Will; M Perricaudet; M Levrero
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

3.  Biosynthesis of alpha fetoprotein by MCF-7 human breast cancer cells.

Authors:  E J Sarcione; D Hart
Journal:  Int J Cancer       Date:  1985-03-15       Impact factor: 7.396

4.  The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.

Authors:  O Terradillos; O Billet; C A Renard; R Levy; T Molina; P Briand; M A Buendia
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

5.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

Review 6.  Structural and functional mapping of alpha-fetoprotein.

Authors:  A A Terentiev; N T Moldogazieva
Journal:  Biochemistry (Mosc)       Date:  2006-02       Impact factor: 2.487

7.  Widespread microRNA repression by Myc contributes to tumorigenesis.

Authors:  Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

8.  Detection and measurement of alpha-fetoprotein in human breast cancer cytosol after treatment with 0.4 M potassium chloride.

Authors:  E J Sarcione; M Zloty; D S Delluomo; G Mizejewski; H Jacobson
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

Review 9.  Biological roles of alpha-fetoprotein during pregnancy and perinatal development.

Authors:  Gerald J Mizejewski
Journal:  Exp Biol Med (Maywood)       Date:  2004-06

10.  Is miR-29 an oncogene or tumor suppressor in CLL?

Authors:  Yuri Pekarsky; Carlo M Croce
Journal:  Oncotarget       Date:  2010-07
View more
  44 in total

1.  DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.

Authors:  C Pistore; E Giannoni; T Colangelo; F Rizzo; E Magnani; L Muccillo; G Giurato; M Mancini; S Rizzo; M Riccardi; N Sahnane; V Del Vescovo; K Kishore; M Mandruzzato; F Macchi; M Pelizzola; M A Denti; D Furlan; A Weisz; V Colantuoni; P Chiarugi; I M Bonapace
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

Review 2.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 3.  Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target.

Authors:  Yuting Wu; Xiaoming Meng; Cheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-05-01

4.  MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling.

Authors:  Rui-Min Chang; Jiang-Feng Xu; Feng Fang; Hao Yang; Lian-Yue Yang
Journal:  Tumour Biol       Date:  2016-02-10

5.  Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Authors:  Andrew Gabrielson; Yunan Wu; Hongkun Wang; Jiji Jiang; Bhaskar Kallakury; Zoran Gatalica; Sandeep Reddy; David Kleiner; Thomas Fishbein; Lynt Johnson; Eddie Island; Rohit Satoskar; Filip Banovac; Reena Jha; Jaydeep Kachhela; Perry Feng; Tiger Zhang; Anteneh Tesfaye; Petra Prins; Christopher Loffredo; John Marshall; Louis Weiner; Michael Atkins; Aiwu Ruth He
Journal:  Cancer Immunol Res       Date:  2016-03-11       Impact factor: 11.151

6.  MiR-141 targets ZEB2 to suppress HCC progression.

Authors:  Shi-Min Wu; Hong-Wu Ai; Ding-Yu Zhang; Xiao-Qun Han; Qin Pan; Feng-Ling Luo; Xiao-Lian Zhang
Journal:  Tumour Biol       Date:  2014-07-10

7.  MicroRNA-29 family inhibits rhabdomyosarcoma formation and progression by regulating GEFT function.

Authors:  Yang Wang; Liang Zhang; Yuweng Pang; Lingxie Song; Hao Shang; Zhenzhen Li; Qianqian Liu; Yangyang Zhang; Xiaomeng Wang; Qianru Li; Qiaochu Zhang; Chunxia Liu; Feng Li
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

8.  miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Tumour Biol       Date:  2015-11-12

9.  DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma.

Authors:  Mona M Hassouna; Mary Naguib; Enas M Radwan; Mohamed Abdel-Samiee; Suzanne Estaphan; Eman Abdelsameea
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01

10.  MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA.

Authors:  Ya-Ling Yang; Ming-Chao Tsai; Yen-Hsiang Chang; Chen-Chen Wang; Pei-Yi Chu; Hung-Yu Lin; Ying-Hsien Huang
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.